These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21899511)

  • 1. PD-1 and autoimmunity.
    Kasagi S; Kawano S; Kumagai S
    Crit Rev Immunol; 2011; 31(4):265-95. PubMed ID: 21899511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.
    Zhang B; Chikuma S; Hori S; Fagarasan S; Honjo T
    Proc Natl Acad Sci U S A; 2016 Jul; 113(30):8490-5. PubMed ID: 27410049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death-1 pathway in cancer and autoimmunity.
    Pedoeem A; Azoulay-Alfaguter I; Strazza M; Silverman GJ; Mor A
    Clin Immunol; 2014 Jul; 153(1):145-52. PubMed ID: 24780173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PD-1/PD-Ls pathway and autoimmune diseases.
    Dai S; Jia R; Zhang X; Fang Q; Huang L
    Cell Immunol; 2014 Jul; 290(1):72-9. PubMed ID: 24908630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+ T cells undergo activation and programmed death-1 repression in the liver of aged Ae2a,b-/- mice favoring autoimmune cholangitis.
    Concepcion AR; Salas JT; Sáez E; Sarvide S; Ferrer A; Portu A; Uriarte I; Hervás-Stubbs S; Oude Elferink RP; Prieto J; Medina JF
    Oncotarget; 2015 Oct; 6(30):28588-606. PubMed ID: 26396175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell costimulatory pathways: blockade for autoimmunity.
    Najafian N; Khoury SJ
    Expert Opin Biol Ther; 2003 Apr; 3(2):227-36. PubMed ID: 12662138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L and autoimmunity: A growing relationship.
    Zamani MR; Aslani S; Salmaninejad A; Javan MR; Rezaei N
    Cell Immunol; 2016 Dec; 310():27-41. PubMed ID: 27660198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression.
    Gianchecchi E; Fierabracci A
    Front Immunol; 2018; 9():2374. PubMed ID: 30386337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity.
    Gianchecchi E; Delfino DV; Fierabracci A
    Autoimmun Rev; 2013 Sep; 12(11):1091-100. PubMed ID: 23792703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell metabolism and susceptibility to autoimmune diseases.
    Galgani M; De Rosa V; Matarese G
    Mol Immunol; 2015 Dec; 68(2 Pt C):558-63. PubMed ID: 26265113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.
    Yokosuka T; Takamatsu M; Kobayashi-Imanishi W; Hashimoto-Tane A; Azuma M; Saito T
    J Exp Med; 2012 Jun; 209(6):1201-17. PubMed ID: 22641383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell receptor transgenic mice in the study of autoimmune diseases.
    Lafaille JJ
    J Autoimmun; 2004 Mar; 22(2):95-106. PubMed ID: 14987736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell activation in autoimmune and inflammatory diseases.
    Perkins DL
    Curr Opin Nephrol Hypertens; 1998 May; 7(3):297-303. PubMed ID: 9617561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
    Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
    J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmunity risk alleles in costimulation pathways.
    Maier LM; Hafler DA
    Immunol Rev; 2009 May; 229(1):322-36. PubMed ID: 19426231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis.
    Czaja AJ
    Autoimmunity; 2019 Jun; 52(4):144-160. PubMed ID: 31298041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ.
    Oftedal BE; Ardesjö Lundgren B; Hamm D; Gan PY; Holdsworth SR; Hahn CN; Schreiber AW; Scott HS
    J Autoimmun; 2017 Jul; 81():24-33. PubMed ID: 28318808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection.
    McKinney EF; Lee JC; Jayne DR; Lyons PA; Smith KG
    Nature; 2015 Jul; 523(7562):612-6. PubMed ID: 26123020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions.
    Tocheva AS; Peled M; Strazza M; Adam KR; Lerrer S; Nayak S; Azoulay-Alfaguter I; Foster CJR; Philips EA; Neel BG; Ueberheide B; Mor A
    J Biol Chem; 2020 Dec; 295(52):18036-18050. PubMed ID: 33077516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.